Galapagos Genomics
|
Formerly called
|
Galapagos Genomics NV |
|---|---|
| Naamloze vennootschap | |
| Traded as |
Euronext: GLPG NASDAQ: GLPG |
| Industry | Pharmaceutical |
| Founded | 1999 |
| Headquarters | Mechelen, Belgium |
|
Key people
|
Onno van de Stolpe (CEO), Raj Parekh (Chairman) |
| Products | filgotinib; GLPG1205; GLPG0778 |
| Revenue | €151.6 million (2016) |
| Profit | €54.0 million (2016) |
| Total assets | €1,083 million (end 2016) |
| Total equity | €758.7 million (end 2016) |
|
Number of employees
|
508 (end 2016) |
| Website | www |
Galapagos NV (formerly known as Galapagos Genomics) is a Belgo-Dutch pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville and Zagreb. The CEO is the Dutchman Onno van de Stolpe.
Currently it is developing drugs against rheumatoid arthritis, crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis.
Galapagos Genomics NV was founded in 1999 as a joint venture between Crucell and Tibotec. The company later changed its name to Galapagos NV and completed its initial public offering on Euronext Amsterdam and Euronext Brussels in May 2005.
The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.
Coordinates: 51°03′19″N 4°27′08″E / 51.05528°N 4.45222°E
...
Wikipedia